8.49
0.00%
+0.00
Elicio Therapeutics Inc. stock is currently priced at $8.49, with a 24-hour trading volume of 10,282.
It has seen a +0.00% increased in the last 24 hours and a -12.02% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.37 pivot point. If it approaches the $8.62 resistance level, significant changes may occur.
Previous Close:
$8.49
Open:
$8.38
24h Volume:
10,282
Market Cap:
$87.19M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3202
EPS:
-26.5174
Net Cash Flow:
$-66.04M
1W Performance:
+5.07%
1M Performance:
-12.02%
6M Performance:
+25.59%
1Y Performance:
+0.00%
Elicio Therapeutics Inc. Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc.
Sector
Industry
Phone
857-209-0050
Address
451 D Street, 5th Floor Suite 501, Boston
Elicio Therapeutics Inc. Stock (ELTX) Latest News
(ELTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Stock Traders Daily
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in ... - GlobeNewswire
GlobeNewswire
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in ... - Yahoo Finance
Yahoo Finance
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 - InvestorPlace
InvestorPlace
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
GlobeNewswire
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates - Yahoo Finance
Yahoo Finance
Elicio Therapeutics Inc. Stock (ELTX) Financials Data
Elicio Therapeutics Inc. (ELTX) Net Income 2024
ELTX net income (TTM) was -$33.82 million for the quarter ending December 31, 2023, a -42.72% decrease year-over-year.
Elicio Therapeutics Inc. (ELTX) Cash Flow 2024
ELTX recorded a free cash flow (TTM) of -$66.04 million for the quarter ending September 30, 2023.
Elicio Therapeutics Inc. (ELTX) Earnings per Share 2024
ELTX earnings per share (TTM) was -$25.59 for the quarter ending December 31, 2023, a +45.26% growth year-over-year.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):